Vascular Therapies
Get Full AccessDescription
- Vascular Therapies, Inc., a privately-held late-stage biopharmaceutical company, is developing the Sirolimus-eluting collagen implant for local, perivascular drug delivery. The goal of this patent protected, innovative therapeutic approach is to address the problem of hemodialysis vascular access failure with the intent of bridging an important unmet medical need in patients with kidney failure. The product is regulated as a drug in the US, EU and Japan and Sirolimus has Orphan Drug status for the dialysis vascular access indications in the U.S. and E.UFounded in 2001, Vascular Therapies is based in Cresskill, NJ.
-
Headquarters:105 Union Avenue , Cresskill, New Jersey, United States
More -
Phone Number: +1 201-266-8310
-
Website: https://www.vasculartx.com
-
Employees:8
-
Revenue:$1 - 10M
-
Legal Name:Vascular Therapies
-
Vascular Therapies's Social Media
-
Is this data correct?
-
| NAICS Code: 811219 |
Show More
Sell more in less time!
Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!
Frequently Asked Questions regarding Vascular Therapies
-
Where are Vascular Therapies's Headquarters?
Vascular Therapies's Headquarters are in 105 Union Avenue ,Cresskill,New Jersey,United States
-
What is Vascular Therapies's phone number?
Vascular Therapies's phone number is +1 201-266-8310
-
What is Vascular Therapies's official website?
Vascular Therapies's official website is https://www.vasculartx.com
-
What is Vascular Therapies's Revenue?
Vascular Therapies's revenue is $1 - 10M
-
What is Vascular Therapies's NAICS code?
Vascular Therapies's NAICS code is 811219
-
How many employees are working in Vascular Therapies
Vascular Therapies has 8 employees
-
What is Vascular Therapies's Industry?
Vascular Therapies is in the industry of Pharmaceuticals
-
Who is Vascular Therapies's CEO?
Vascular Therapies's CEO is Samuel Liang